Please ensure Javascript is enabled for purposes of website accessibility

Why Kezar Life Sciences Is Down Today

By Prosper Junior Bakiny – Updated Jun 9, 2020 at 4:16PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's public offering of common stock doesn't exactly thrill investors.

What happened?

Shares of Kezar Life Sciences (KZR -3.29%) are down by 11.7% as of 3:12 p.m. EDT on Tuesday, following the company's announcement of the pricing of a public offering of common stock. Kezar Life Sciences made this announcement after the market closed on Monday.

So what

Kezar Life Sciences -- whose stock price was above $6.20 at the close of market on Monday -- has priced its public offering of 7,590,909 common shares at $5.50 per share. Further, the company is issuing 909,091 shares of its common stock to holders of pre-funded warrants at $5.499 per underlying share; pre-funded warrants provide their holders with the right to purchase shares of a company at a later date. Kezar Life Sciences is hoping to raise approximately $46.7 million from this public offering, which will close on Jun. 11.

Five downward-pointing arrows on a blackboard.

Image Source: Getty Images.

The company expects to use the proceeds from this round of fundraising to "fund the research and development of its product candidates, acquire or license products or technologies that are complementary to its own ... and for working capital and general corporate purposes." With this public offering of common stock set to dilute Kezar Life Sciences' existing shareholders' equity, no wonder investors aren't thrilled. 

Now what

Kezar Life Sciences recently released results from a clinical trial evaluating the safety and tolerability of KZR-616 in patients with systemic lupus erythematosus (SLE) with and without nephritis. The results from this trial were positive. According to a company statement, "Overall, improvements were seen across seven measures of disease activity, and two of two patients with lupus nephritis (LN) experienced a greater than 50% reduction in proteinuria, a biomarker of disease severity."

Still, Kezar Life Sciences is a clinical-stage biotech company with no products currently on the market. The company reported no revenue during the first quarter, a $10 million net loss, and it had $123.4 million in cash and cash equivalents as of March 31. Given these factors, it isn't too surprising that the company decided to conduct a public offering of common stock. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Kezar Life Sciences, Inc. Stock Quote
Kezar Life Sciences, Inc.
$8.51 (-3.29%) $0.29

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.